Advanced Filters
noise

Lund, Sweden Clinical Trials

A listing of Lund, Sweden clinical trials actively recruiting patients volunteers.

Found 182 clinical trials
K KristinaHåkan Ingemarsson, MD, PhD

Aerobic Versus Leisure Group for Adolescents With Depression

The aim is to evaluate aerobic group exercise versus leisure group activities in adolescents with mild to moderate depression. Primary outcome is Children's Depression Rating Scale - Revised (CDRS-R). Secondary outcomes are Clinical Global Impressions - Severity and Improvement scales (CGI), self-reported Quick Inventory of Depression Symptomatology (QIDS- A17-SR), the …

13 - 17 years of age All Phase N/A
G Gustav Cornefjord, MD

The With Or Without Olecranon K-wires Trial

Fractures of the elbow tip (olecranon) that leave the elbow joint stable but where the fracture ends are separated (Mayo type 2a and 2b) can be treated with pins and a metal wire (tension band wiring, TBW) or metal wiring alone (cerclage fixation, CF ). Previous studies have reported high …

18 years of age All Phase N/A
A Ann Hellström, MD, PhD

Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants

Background and study aims When an infant is born premature, the blood vessels in the eyes have not developed fully on the retina, and can start to grow incorrectly and result in blindness. To prevent this from happening, premature infants are often screened, and treated with laser or injections into …

- 30 years of age All Phase 1

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2). …

18 years of age All Phase 3
M Maria Cronhjort, PhD

Treatment of Post-covid Syndrome in Patients Treated in Intensive Care

The present study is a pilot randomized controlled trial, which identifies and diagnoses mental health problems in survivors of critical COVID-19 infection at 12 months post-ICU care, and randomize patients to either an ACT-enforced CBT intervention, or to treatment as usual.

18 years of age All Phase N/A
G Guyla Nagy, MD

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessary and should be avoided. This includes but is not limited to patients with a preoperative diagnosis …

18 years of age Female Phase 3
F Folke Sjöberg

A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers

The aim of the study is to assess safety, tolerability and preliminary efficacy of XSTEM-VLU when administered as a single topical dose to patients with difficult-to-heal venous leg ulcers. The study is randomised and the patients will receive either XSTEM-VLU or vehicle as add on to standard wound care. The …

18 years of age All Phase 1/2
C Carl-Fredrik Rönnow, MD, PhD

Magnetomotoric Ultrasound (MMUS) in Rectal Cancer

Magnetomotoric ultrasound, combines conventional ultrasound with a time-varying magnetic field. The aim is to improve diagnosis of mesolectal lymph nodes.

18 years of age All Phase N/A
J Jan Sundberg, RN

Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.

A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA <0.70 ng/ml) after prostatectomy.

18 years of age Male Phase 3
L Luigi De Petris, PhD

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

This is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC. Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12 months

18 years of age All Phase 2

Simplify language using AI